GenSight will participate to the American Academy of Ophthalmology to be held in virtual format and will give oral presentations on its lead product candidates, LUMEVOQ® (GS010), to treat Leber’s Hereditary Optic Neuropathy (LHON) and GS030, to treat Retinitis Pigmentosa (RP)

LUMEVOQ® (GS010) – Leber’s Hereditary Optic Neuropathy (LHON) 

Paper Title – Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy: Final Results of the Phase 3 RESCUE and REVERSE Trials

Abstract Number:  30064033

Presenting Author:  Patrick Yu-Wai-Man, FRCOphth, MBBS, PHD, Senior Lecturer and Honorary Consultant Ophthalmologist at the University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, London (UK)

Session:  PA030

Topic:  Neuro-Ophthalmology

Date – Time:  Available On Demand


GS030 – Optogenetics in Retinitis Pigmentosa

Paper Title – Optogenetics in the Clinic: PIONEER, a Phase 1/2 Gene Therapy Program for Non syndromic RP

Abstract Number:  30064259

Presenting Author:  Joseph N Martel MD, Assistant Professor of Ophthalmology Retina and Vitreous Servious, UPMC Eye Center – Eye & Ear Institute, Pittsburg, PA (US)

Session:  PA056

Topic:  Retina, Vitreous

date – Time:  Available On Demand